Stratz T, Schochat T, Hrycaj P, Lacki J, Mennet P, Färber L, Schweiger C, Müller W
Hochrhein-Institut für Rehabilitationsforschung, Bad Säckingen.
Z Rheumatol. 1994 Nov-Dec;53(6):335-8.
In more than 40% of patients with fibromyalgia a marked influence on the pain in the skeletal system with a decrease of the tenderness at "tenderpoints" can be achieved by blocking the 5-HT3-receptors with ondansetron or tropisetron-hydrochloride. Physical complaints and vegetative signs also improve. It is discussed if patients not responding to therapy with ondansetron or tropisetron-hydrochloride have to be discriminated as a subgroup of fibromyalgia. More investigations are needed to confirm the described effects.